ABCB1 p.Tyr307Cys
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 24349290
[PubMed]
Chufan EE et al: "Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1)."
No.
Sentence
Comment
7
In addition, the transport of six fluorescent substrates in HeLa cells expressing triple mutant (Y307C/Q725C/V982C) Pgp is also not significantly altered, showing that substrates bound at secondary sites are still transported.
X
ABCB1 p.Tyr307Cys 24349290:7:97
status: NEW55 For biochemical studies, crude membranes were prepared from High-Five insect cells infected with baculovirus coding for cysless WT, single mutants Y307C, F343C, Q725C, F728C, F978C, V982C, double mutants Y307C/V982C, F343C/V982C, Q725C/V982C, F728C/V982C, and a triple mutant Y307C/Q725C/V982C.
X
ABCB1 p.Tyr307Cys 24349290:55:147
status: NEWX
ABCB1 p.Tyr307Cys 24349290:55:204
status: NEWX
ABCB1 p.Tyr307Cys 24349290:55:276
status: NEW61 However, CsA, tariquidar and valinomycin lose almost completely this ability to inhibit IAAP photo-labeling when residues Y307, Q725 and V982 are mutated to cysteine (i.e., Y307C/Q725C/V982C mutant).
X
ABCB1 p.Tyr307Cys 24349290:61:173
status: NEW73 Inhibition of IAAP labeling for single mutants Q725C, Y307C, F728C and V982C (upper graphs) and for double Q725C/V982C, Y307C/V982C, F728C/V982C, and triple Y307C/Q725C/V982C (lower graphs) mutants at different concentrations of (A) CsA and (B) tariquidar, are shown. Inhibition of IAAP labeling for cysless WT is included in all graphs, as a reference.
X
ABCB1 p.Tyr307Cys 24349290:73:54
status: NEWX
ABCB1 p.Tyr307Cys 24349290:73:120
status: NEWX
ABCB1 p.Tyr307Cys 24349290:73:157
status: NEW74 Autoradiograms corresponding to cysless, V982C and Y307C/Q725C/V982C, as representative examples of complete inhibition, partial inhibition and no inhibition of IAAP-labeling, respectively, are shown at the top of the figure.
X
ABCB1 p.Tyr307Cys 24349290:74:51
status: NEW83 The rest of the mutants, Q725C, Y307C (and their corresponding double and triple mutants) and F728 show intermediate levels of basal ATPase activity.
X
ABCB1 p.Tyr307Cys 24349290:83:32
status: NEW90 Mutation(s) CsA Tariquidar Max Inhibition (%) IC50 (&#b5;M) Max Inhibition (%) IC50 (&#b5;M) Cysless WT 86 &#b1; 3 0.05 &#b1; 0.01 97 &#b1; 4 0.14 &#b1; 0.03 Q725C 24 &#b1; 4 -- 37 -- Q725C/V982C 11 -- 22 -- Y307C 35 &#b1; 2 -- ND -- Y307C/V982C 46 -- ND -- F728C 48 -- 40 -- F728C/V982C 49 -- ND -- V982C 56 0.40 64 0.70 Y307C/Q725C/ V982C 12 -- 23 -- F978C 86 0.54 73 3.6 Mean values with standard errors are reported when more than two experiments were carried out; otherwise only average values are reported.
X
ABCB1 p.Tyr307Cys 24349290:90:208
status: NEWX
ABCB1 p.Tyr307Cys 24349290:90:234
status: NEWX
ABCB1 p.Tyr307Cys 24349290:90:322
status: NEW94 It is interesting to observe that the effect of the V982C mutation is not dominant in the rest of the double mutants and even in the triple mutant Y307C/Q725C/V982C, in which case valinomycin does stimulate ATP hydrolysis.
X
ABCB1 p.Tyr307Cys 24349290:94:147
status: NEW95 FSBA also stimulates the ATP hydrolysis of most of the mutants, with the exception of the double F728C/V982C and the triple Y307C/Q725C/V982C mutant.
X
ABCB1 p.Tyr307Cys 24349290:95:124
status: NEW108 In Figure 4A, representative histograms show the cell surface expression for single (Y307C), double (Y307C/V982C) and triple (Y307C/ Q725C/V982C) mutants.
X
ABCB1 p.Tyr307Cys 24349290:108:85
status: NEWX
ABCB1 p.Tyr307Cys 24349290:108:101
status: NEWX
ABCB1 p.Tyr307Cys 24349290:108:126
status: NEW114 Even with the triple (Y307C/Q725C/V982C) mutant the efflux of none of the above-mentioned substrates is completely abolished, although many of these substrates are transported at lower levels when compared to the cysless WT Pgp (Table 2).
X
ABCB1 p.Tyr307Cys 24349290:114:22
status: NEW116 Figure 5A shows the transport of rhodamine 123 (Rh123), which is normal for the single (Y307C) and double (Y307C/V982C) mutants but is decreased considerably for the triple (Y307C/Q725C/V982C) mutant.
X
ABCB1 p.Tyr307Cys 24349290:116:88
status: NEWX
ABCB1 p.Tyr307Cys 24349290:116:107
status: NEWX
ABCB1 p.Tyr307Cys 24349290:116:174
status: NEW123 NBD-CsA loses the ability to inhibit the IAAP labeling of the triple (Y307C/Q725C/V982C) Figure 2.
X
ABCB1 p.Tyr307Cys 24349290:123:70
status: NEW151 Nonetheless, Y307C/V982C and the triple mutant Y307C/ Q725C/V982C show some rescue of the NBD-CsA transport.
X
ABCB1 p.Tyr307Cys 24349290:151:13
status: NEWX
ABCB1 p.Tyr307Cys 24349290:151:47
status: NEW152 This can most likely be attributed to the presence of the Y307C mutation, as this particular double mutant exhibits about 50-60% transport function with respect to NBD-CsA (Table 2).
X
ABCB1 p.Tyr307Cys 24349290:152:58
status: NEW159 (A) The left panel shows the cell surface localization of Y307C with human Pgp-specific monoclonal antibody MRK-16 labeling as detected by green fluorescence detector.
X
ABCB1 p.Tyr307Cys 24349290:159:58
status: NEW160 The middle panel shows the same for the double mutant Y307C/V982C, and the right panel for the triple mutant Y307C/Q725C/V982C.
X
ABCB1 p.Tyr307Cys 24349290:160:54
status: NEWX
ABCB1 p.Tyr307Cys 24349290:160:109
status: NEW162 The conformation sensitivity towards CsA of single (Y307C), double (Y307C/V982C) and triple (Y307C/Q725C/V982C) mutants was similar to cysless WT Pgp, as shown in the three panels, respectively.
X
ABCB1 p.Tyr307Cys 24349290:162:52
status: NEWX
ABCB1 p.Tyr307Cys 24349290:162:68
status: NEWX
ABCB1 p.Tyr307Cys 24349290:162:93
status: NEW175 Mutation(s) Cell surface expression Transport function CalAM BD-PRA NBD-CsA Rh123 Dauno BD-PAC Y307C 100 90-100 80-90 90-100 90-100 90-100 90-100 Q725C 100 90-100 90-100 90-100 90-100 90-100 90-100 F728C 100 90-100 80-90 90-100 90-100 90-100 90-100 V982C 100 90-100 80-100 <10 90-100 90-100 90-100 F343C 50-60 90-100 80-100 90-100 90-100 90-100 90-100 F978C 100 90-100 90-100 90-100 90-100 90-100 90-100 Y307C/ V982C 100 90-100 50-60 50-60 90-100 90-100 90-100 Q725C/ V982C 100 90-100 80-90 <20 90-100 90-100 90-100 F728C/ V982C 30-40 55-65 30-40 <20 70-80 50-60 90-100 F343C/ V982C 70-80 90-100 80-90 <20 90-100 90-100 90-100 Y307/ Q725C/ V982C 100 90-100 30-40 50-60 70-80 60-70 90-100 For cell surface expression, the cells were incubated with MRK-16 antibody for 30 min followed by FITC-labeled anti-mouse secondary antibody for 30 min.
X
ABCB1 p.Tyr307Cys 24349290:175:95
status: NEWX
ABCB1 p.Tyr307Cys 24349290:175:404
status: NEW211 The transport functions of single (Y307C), double (Y307/V982C) and triple (Y307C/Q725C/V982C) mutants are differentially affected.
X
ABCB1 p.Tyr307Cys 24349290:211:35
status: NEWX
ABCB1 p.Tyr307Cys 24349290:211:75
status: NEW240 The partial inhibition of IAAP labeling observed for single mutants (Y307C, Q725C, F728C, and V982C) and even double mutants (Y307C/V982C, Q725C/V982C, F728C/V982C) is indicative of some drug interaction with Pgp (Figure 1).
X
ABCB1 p.Tyr307Cys 24349290:240:69
status: NEWX
ABCB1 p.Tyr307Cys 24349290:240:126
status: NEW251 In all mutants, even the triple Y307C/Q725C/V982C, ATP hydrolysis is inhibited by both CsA and tariquidar.
X
ABCB1 p.Tyr307Cys 24349290:251:32
status: NEW257 In steady-state conditions, calcein-AM and bodipy-placitaxel are transported by the triple (Y307C/Q725C/V982C) mutant to the same extent as cysless WT Pgp.
X
ABCB1 p.Tyr307Cys 24349290:257:92
status: NEW261 Therefore, NBD-CsA does not bind to its primary site on Y307C/Q725C/V982C, but to a secondary site, where it is transported at 50-60% of the rate of cysless WT Pgp.
X
ABCB1 p.Tyr307Cys 24349290:261:56
status: NEW328 Effect of QZ59-SSS-sulfur on the photocrosslinking of cysless WT and mutant Pgpswith IAAP. Inhibition of IAAP-labeling for cysless WT and for triple mutant Y307C/Q725C/V982C at different concentrations of QZ59-SSS-sulfur are shown (graph).
X
ABCB1 p.Tyr307Cys 24349290:328:156
status: NEW333 Inhibition of IAAP-labeling for single mutants Q725C, Y307C and V982C (upper graph) and for double (Q725C/V982C and Y307C/ V982C) and triple (Y307C/Q725C/V982C) mutants (lower graph) at different concentrations of valinomycin are shown. Inhibition of IAAP-labeling of cysless WT is included in both graphs, as a reference.
X
ABCB1 p.Tyr307Cys 24349290:333:54
status: NEWX
ABCB1 p.Tyr307Cys 24349290:333:116
status: NEWX
ABCB1 p.Tyr307Cys 24349290:333:142
status: NEW338 Effect of FSBA on the photocrosslinking of cysless WT and mutant Pgps with IAAP. Inhibition of IAAP-labeling of cysless WT and triple (Y307C/Q725C/V982C) mutant at different concentrations of FSBA are shown (graph).
X
ABCB1 p.Tyr307Cys 24349290:338:135
status: NEW